{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:15:53Z","timestamp":1790716553918,"version":"4.1.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Management of gram-negative bloodstream infections (GN-BSIs) with oral antibiotics is highly variable.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the transition from intravenous (IV) to oral antibiotics, including selection, timing, and associated clinical and microbial characteristics, among hospitalized patients with GN-BSIs.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A retrospective cohort study was conducted of 4581 hospitalized adults with GN-BSIs at 24 US hospitals between January 1 and December 31, 2019. Patients were excluded if they died within 72 hours. Patients were excluded from the oral therapy group if transition occurred after day 7. Statistical analysis was conducted from July 2022 to October 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Administration of antibiotics for GN-BSIs.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Baseline characteristics and clinical parameters reflecting severity of illness were evaluated in groups receiving oral and IV therapy. The prevalence of transition from IV to oral antibiotics by day 7, median day of transition, sources of infection, and oral antibiotic selection were assessed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of a total of 4581 episodes with GN-BSIs (median age, 67 years [IQR, 55-77 years]; 2389 men [52.2%]), 1969 patients (43.0%) receiving IV antibiotics were transitioned to oral antibiotics by day 7. Patients maintained on IV therapy were more likely than those transitioned to oral therapy to be immunosuppressed (833 of 2612 [31.9%] vs 485 of 1969 [24.6%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), require intensive care unit admission (1033 of 2612 [39.5%] vs 334 of 1969 [17.0%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), have fever or hypotension as of day 5 (423 of 2612 [16.2%] vs 49 of 1969 [2.5%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), require kidney replacement therapy (280 of 2612 [10.7%] vs 63 of 1969 [3.2%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), and less likely to have source control within 7 days (1852 of 2612 [70.9%] vs 1577 of 1969 [80.1%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Transitioning patients from IV to oral therapy by day 7 was highly variable across hospitals, ranging from 25.8% (66 of 256) to 65.9% (27 of 41). A total of 4109 patients (89.7%) achieved clinical stability within 5 days. For the 3429 episodes (74.9%) with successful source control by day 7, the median day of source control was day 2 (IQR, 1-3 days) for the oral group and day 2 (IQR, 1-4 days) for the IV group (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Common infection sources among patients administered oral therapy were the urinary tract (1277 of 1969 [64.9%]), hepatobiliary (239 of 1969 [12.1%]), and intra-abdominal (194 of 1969 [9.9%]). The median day of oral transition was 5 (IQR, 4-6 days). Total duration of antibiotic treatment was significantly shorter among the oral group than the IV group (median, 11 days [IQR, 9-14 days] vs median, 13 days [IQR, 8-16 days];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001]. Fluoroquinolones (62.2% [1224 of 1969]), followed by \u03b2-lactams (28.3% [558 of 1969]) and trimethoprim-sulfamethoxazole (11.5% [227 of 1969]), were the most commonly prescribed oral antibiotics.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of 4581 episodes of GN-BSIs, transition to oral antibiotic therapy by day 7 occurred in fewer than half of episodes, principally with fluoroquinolones, although this practice varied significantly between hospitals. There may have been additional opportunities for earlier and more frequent oral antibiotic transitions because most patients demonstrated clinical stability by day 5.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.49864","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T11:01:58Z","timestamp":1704193318000},"page":"e2349864","source":"Crossref","is-referenced-by-count":26,"title":["Transition to Oral Antibiotic Therapy for Hospitalized Adults With Gram-Negative Bloodstream Infections"],"prefix":"10.1001","volume":"7","author":[{"given":"Drew W.","family":"Engers","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases, Trinity Health, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranita D.","family":"Tamma","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suiyini","family":"Fiawoo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Fong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Utah Health, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ripal","family":"Jariwala","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Denver Health, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald E.","family":"Kendall","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"McCreary","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal K.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Intermountain Health, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine C.","family":"Shihadeh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Denver Health, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judianne","family":"Slish","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Rochester Medicine\u2013Highland Hospital, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor C.","family":"Van Schooneveld","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag N.","family":"Malani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases, Trinity Health, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"issue":"6","key":"zoi231450r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106451","article-title":"Variability in oral antibiotic step-down therapy in the management of gram-negative bloodstream infections.","volume":"58","author":"Thaden","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"zoi231450r2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijantimicag.2019.05.011","article-title":"Duration of therapy recommended for bacteraemic illness varies widely amongst clinicians.","volume":"54","author":"Alwan","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"zoi231450r3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"6","key":"zoi231450r4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ajic.2005.03.010","article-title":"Nosocomial bloodstream infections in ICU and non-ICU patients.","volume":"33","author":"Suljagic","year":"2005","journal-title":"Am J Infect Control"},{"issue":"9","key":"zoi231450r7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938","article-title":"Association of adverse events with antibiotic use in hospitalized patients.","volume":"177","author":"Tamma","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"7","key":"zoi231450r8","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial.","volume":"69","author":"Yahav","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"11","key":"zoi231450r9","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1093\/cid\/ciz223","article-title":"Antibiotic therapy for Pseudomonas aeruginosa bloodstream infections: how long is long enough?","volume":"69","author":"Fabre","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"21","key":"zoi231450r10","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein\u2013guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial.","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"zoi231450r11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/cid\/cix767","article-title":"Comparing the outcomes of adults with Enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort.","volume":"66","author":"Chotiprasitsakul","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"6","key":"zoi231450r12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/EDE.0b013e3181577654","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"18","author":"von Elm","year":"2007","journal-title":"Epidemiology"},{"key":"zoi231450r13","journal-title":"J Chronic Dis"},{"key":"zoi231450r14","doi-asserted-by":"publisher","journal-title":"Int J Antimicrob Agents","DOI":"10.1016\/S0924-8579(98)00060-0"},{"issue":"12","key":"zoi231450r15","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1093\/cid\/ciz1197","article-title":"Effectiveness of shorter versus longer durations of therapy for common inpatient infections associated with bacteremia: a multicenter, propensity-weighted cohort study.","volume":"71","author":"Hojat","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"10","key":"zoi231450r16","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab434","article-title":"Optimizing the management of uncomplicated gram-negative bloodstream infections: consensus guidance using a modified Delphi process.","volume":"8","author":"Heil","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"zoi231450r17","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial.","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"issue":"2, pt 1","key":"zoi231450r18","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1097\/01.ju.0000106191.11936.64","article-title":"Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis.","volume":"171","author":"Talan","year":"2004","journal-title":"J Urol"},{"issue":"11","key":"zoi231450r19","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/phar.2017.37.issue-11","article-title":"Intravenous-only or intravenous transitioned to oral antimicrobials for Enterobacteriaceae-associated bacteremic urinary tract infection.","volume":"37","author":"Rieger","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"3","key":"zoi231450r20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1001\/jamainternmed.2018.6226","article-title":"Association of 30-day mortality with oral step-down vs continued intravenous therapy in patients hospitalized with Enterobacteriaceae bacteremia.","volume":"179","author":"Tamma","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"6","key":"zoi231450r21","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/106002809603000605","article-title":"Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis.","volume":"30","author":"Amodio-Groton","year":"1996","journal-title":"Ann Pharmacother"},{"issue":"10","key":"zoi231450r22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz364","article-title":"Oral fluoroquinolone or trimethoprim-sulfamethoxazole vs. \u00df-lactams as step-down therapy for Enterobacteriaceae bacteremia: systematic review and meta-analysis.","volume":"6","author":"Punjabi","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"zoi231450r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.20166","article-title":"Oral \u00df-lactam antibiotics vs fluoroquinolones or trimethoprim-sulfamethoxazole for definitive treatment of Enterobacterales bacteremia from a urine source.","volume":"3","author":"Sutton","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi231450r5","unstructured":"World Health Organization. Global Antimicrobial Resistance Surveillance System (GLASS) report: early implementation 2017-2018. Published January 1, 2019. Accessed March 8, 2023. https:\/\/www.who.int\/publications\/i\/item\/9789241515061"},{"key":"zoi231450r6","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Accessed March 9, 2023. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2813452\/engers_2024_oi_231450_1703019071.39363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T11:02:03Z","timestamp":1704193323000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2813452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.49864","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]}}}